Medical Industry Feature

Guest: John Bridges, MD, MS For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape...

Guest: Joshua Milner, M.D. Guest: Eric Silver, M.D. Guest: Steven Lobritto, M.D. On this episode of Advances in Care , host Erin Welsh explores the story behind the GUARDIAN study, where thousands of newborn babies have been screened against rare disease by sequencing their genes, and looking for more conditions than any of the current standard screening panels. First, she hears from Dr. Jordan Or...

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what ques...

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Fran...

Guest: Hans Katzberg, MD Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a complex immune-mediated condition affecting the peripheral nervous system. Join Dr. Hans Katzberg, Professor of Medicine at the University of Toronto, as he explains the pathophysiology behind CIDP, risk factors in disease development, and diagnostic strategies.

Guest: Maria Hordinsky, MD, FAAD Artificial intelligence (AI) is reshaping dermatology care, but integrating it into clinical practice comes with challenges. Dr. Maria Hordinsky explores how clinics must adapt workflows and invest in new technologies to fully harness the potential for AI to drive better hair loss treatment. Dr. Hordinsky is the R. W. Goltz Professor and Vice Chair of Research in t...

Guest: Maria Hordinsky, MD, FAAD From clinical research to direct patient care, dermatology tools powered by artificial intelligence (AI) present a new approach to hair loss treatment. Dr. Maria Hordinsky explains how virtual tattoo technology and at-home devices now provide measurable data, improving patient outcomes and allowing dermatologists to personalize treatment with precision. Dr. Hordins...

Guest: Craig Smith, M.D. On this episode of Advances in Care , host Erin Welsh and Dr. Craig Smith, Chair of the Department of Surgery and Surgeon-in-Chief at NewYork-Presbyterian and Columbia discuss the highlights of Dr. Smith’s 40+ year career as a cardiac surgeon and how the culture of Columbia has been a catalyst for innovation in cardiac care. Dr. Smith describes the excitement of helping to...

Guest: Eva Parker, MD, FAAD Rising temperatures, worsening air quality, and extreme weather events appear to be increasing the prevalence and severity of skin diseases. Dr. Eva Parker, Assistant Professor of Dermatology and Core Faculty at the Center for Biomedical Ethics and Society at Vanderbilt University Medical Center, shares strategies for dermatologists to improve climate literacy, reduce t...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stephen I. Pelton, MD In the last two pre-pandemic flu seasons, approximately half of hospitalizations from influenza in the US were in adults 65 and older. 1,2 A recent real-world study evaluated the relative effectiveness of adjuvanted influenza vaccine versus high-dose vaccine in preventing test-confirmed influenza hospitalizations in this age gro...